Further studies evaluating the clinical significance of the PGC-1α/LARS1/AKT/GSK-3β/β-catenin axis in human colorectal cancer patients and therapeutic potentials of several LARS1 inhibitors in PGC-1α-overexpressing colorectal cancer are needed. This evidence concerns the gene PPARGC1A and colorectal cancer.